Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenoses With a Novel Platinum Chromium Thin-Strut Stent Primary Results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Trial
Dean J Kereiakes, Louis A Cannon, Robert L Feldman, Jeffrey J Popma, Raymond Magorien, Robert Whitbourn, Ira M Dauber, Abram C Rabinowitz, Michael W Ball, Barry Bertolet, Ameer Kabour, Michael C Foster, John C Wang, Paul Underwood, Keith D Dawkins
Journal of the American College of Cardiology | ELSEVIER SCIENCE INC | Published : 2010
Boston Scientific Corporation, Natick, Massachusetts. The PERSEUS WH trial is funded by Boston Scientific Corporation, Natick, Massachusetts. Dr. Kereiakes received research grants from Boston Scientific, Cordis, Medtronic, and Abbott Vascular and serves on the Advisory Boards for Boston Scientific and Abbott Vascular. Dr. Cannon serves on the Advisory Board or Speakers' Bureau for Medtronic, Abbott, and Boston Scientific and holds equity in Boston Scientific, Medtronic, and BioStar Ventures. Dr. Feldman has research grant support from and serves as a consultant for Boston Scientific. Dr. Popma has received personal and institutional research grants from Cordis Corporation and institutional research grants from Boston Scientific and Abbott Vascular. Dr. Magorien serves as a consultant to Boston Scientific and has received grants from Abbott Vascular. Dr. Whitbourn's institution has received a research grant from Boston Scientific. Dr. Rabinowitz has received funds from Boston Scientific to support expert testimony and investigator meeting travel. Dr. Kabour has received honoraria funds from Boston Scientific. Dr. Foster serves on the Speakers' Bureau for Volcano Corporation. Dr. Wang serves on the Medical Advisory Board for Boston Scientific and has received travel funds to attend Medical Advisory Board meetings. Drs. Underwood and Dawkins are full-time employees and stockholders of Boston Scientific Corporation.